Dr. JJ Cheng from the University of Illinois at Urbana-Champaign has developed a helix/random confirmation switchable antimicrobial polypeptides (HRS-AMPs) that are pH...
Dr. JJ Cheng from the University of Illinois at Urbana-Champaign has developed a helix/random confirmation switchable antimicrobial polypeptides (HRS-AMPs) that are pH sensitive and can kill Helicobacter pylori. H pylori, a causative agent of gastric ulcers, lives in the acidic environment of the stomach, and these pH activated antimicrobial peptides could be used to kill H pylori. The polypeptides are inactive until reaching the stomach, thus preserving the microbiota of the rest of the GI tract. In vivo data demonstrates good biodistribution, bioavailability, efficacy, and low toxicity compared to standard treatment for H. pylori infection. Moreover, HRS-AMPs are active against MDR and clinical isolate strains.
Dr. Moore has developed a new drug that could reverse the progression of Alzheimer’s disease. The drug breaks up amyloid fibrils, which are believed to be the root cause...
Dr. Moore has developed a new drug that could reverse the progression of Alzheimer’s disease. The drug breaks up amyloid fibrils, which are believed to be the root cause of the disease. This invention is the first demonstration of a drug that could treat Alzheimer’s disease.
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against Shigellosis, an infectious gastrointestinal disease caused by...
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against Shigellosis, an infectious gastrointestinal disease caused by Shigella bacteria. The protein is a multiepitope fusion antigen (MEFA), incorporating virulence factors which are conserved across multiple Shigella serotypes.
When administered to animals, this fusion protein induces protection against Shigella epithelial cell invasion. Since virulence factors from multiple serotypes are included in the fusion protein, this protection can be extended to the various Shigella serotypes.
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against Shigellosis, an infectious gastrointestinal disease caused by...
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against Shigellosis, an infectious gastrointestinal disease caused by Shigella bacteria. The protein is a multiepitope fusion antigen (MEFA), incorporating virulence factors which are conserved across multiple Shigella serotypes.
When administered to animals, this fusion protein induces protection against Shigella epithelial cell invasion. Since virulence factors from multiple serotypes are included in the fusion protein, this protection can be extended to the various Shigella serotypes.
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against cholera. Cholera is an acute, diarrheal illness caused...
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against cholera. Cholera is an acute, diarrheal illness caused by infection of the intestine with the toxigenic bacterium Vibrio cholerae. The protein is a multiepitope fusion antigen (MEFA), incorporating virulence factors which are conserved across multiple Vibrio serotypes.
When administered to animals, the cholera MEFA is broadly immunogenic and induces protective antibodies against Vibrio. Since virulence factors from multiple serotypes are included in the fusion protein, this protection can be extended to the various Vibrio serotypes.
